Sorry to contribute very little in this amazing thread. However, if no one has pointed out for LBT, i would like it to be added for short term Entry.
LBT: LBT Innovations Limited (Little Bio Tech Gem)
LBT Innovations Limited (LBT, formerly LabTech Systems) is a developer of clinical and diagnostic technology, based in Adelaide, South Australia. LBT owns "MicroStreak" which is a novel agar plate streaking technology.
Share Price: 13c (Year High: 25.5, Year Low: 6.8c) Share Issued: 114M Market Cap: $14.3M Cash at the end of Quarter: $4.52M
2 technology platforms
2 products generating revenue
• Product pipeline in R&D • Established global partners
Snapshot • APAS® joint venture company, Clever Culture Systems AG (Zurich) • Upfront $US2M APAS® payment received • 3 APAS® milestone payments received, each $US1M • $510K ARC Linkage grant for extension of APAS® R&D into new products • $2.01M capital raising through private placement and SPP • APAS® featured at ECCMID 2014, demonstrator model for ECCMID 2015 • Office relocation; new staff: CFO; Quality Manager; US clinical trial coordinator • $250K BioSA grant to initiate LBT’s 3rd product, Woundvue™ • $3M cash refund from ATO R&D Tax Incentive • APAS® clinical trial programme commences
The company’s focus is to:
1. Address inefficient processes & practices in pathology laboratories to report
results sooner and allow doctors to treat patients faster
2. Design automated products using breakthrough technologies
3. Commercialise through international partners
4. Build revenue momentum from PREVI® Isola and the APAS® JV
5. Initiate a new project for wound management based on LBT’s intelligent
imaging platform
After a period of technology development/product commercialisation, LBT is
positioned for profitability & sustained growth
Recent Announcements:
LBT COMPLETES AUSTRALIAN CLINICAL TRIALS OF APAS® TECHNOLOGY
Adelaide, 26 November 2014: Medical technology company LBT Innovations Limited (ASX: LBT) has completed two comprehensive clinical trials of its pioneering culture-plate analysis technology, the Automated Plate Assessment System (APAS®), at the laboratories of Healthscope Pathology in Melbourne and Adelaide.
The trials successfully tested the efficacy of the APAS technology in detecting and reporting the presence of disease causing pathogens in urine samples from a total of 4,300 patients. A full report of the findings is being submitted to the United States Food and Drug Administration (FDA), prior to the commencement of a US trial early in 2015.
LBT is maintaining close consultation with the FDA to confirm that its trial protocols continue to meet the strict guidelines required for a 510(k) de novo submission, which will be required before APAS can be distributed commercially in the US market.
